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Abstract
Hypoxic ischaemic injury can damage the brain at any age. However, the infant brain
displays a unique profile of sensitivity and resistance compared to adult ischaemic stroke
patients. Both pathology and response to treatment are uniquely affected by the molecular
landscape of the neonatal brain. With new revelations in the biology of brain injury in
perinates and neonates being discovered, as global mortality and morbidity increases
research funding into infant brain injury, it is important to raise awareness of the unparal-
leled challenge of treating these young patients. This chapter will review currently known
differences between the infant and adult brain response to hypoxia, and address existing
treatments alongside proposed treatments not yet evaluated by clinical trial.
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1. Introduction
The clinical definition of neonatal hypoxic ischaemic (HI) injury is “asphyxia of the umbilical
blood supply to the human foetus occurring at 36 gestational weeks or later” [1–4]. Neonatal
HI has also been referred to as hypoxic-ischaemic encephalopathy (HIE), where the neonatal
period is interchangeably referred to as “term” [2, 4]. If the injury occurs prior to 36 gestational
weeks, the condition is described as perinatal hypoxia ischaemia.
Neonatal hypoxia ischaemia is diagnosed based on a range of factors which correlate with
clinical outcome [1, 5, 6]. These include: 5-min Apgar score of less than 5 [7, 9]; need for
delivery room intubation or cardiopulmonary resuscitations [8]; umbilical cord arterial pH
below 7.00 [9]; and absence of normal neurological signs, such as the infant sucking reflex
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[7, 10]. These are only a selection of risk factors assessed postnatally, and there is an enormous
range of clinical outcomes amongst infant patients diagnosed with HI [11, 12].
Globally, hypoxia ischaemia is the single most common cause of death and disability in human
neonates [13–15], making further research into pathophysiology and treatment an interna-
tional priority. Persistent disability is common is surviving infants. Clinical outcomes can
range from death to normal neurological profile at 2 years follow-up [16]. Meta-analysis
studies have documented that 5–10% of patients developed a persistent motor disability, with
up to 50% of patients displaying cognitive or sensory disorders in childhood or adolescence
[17–20]. Between 0.7 and 1.2 million infants are born with evidence of hypoxic ischaemic brain
injury every year, accounting for 23% of global infant mortality [21]. Survival rates have
increased since the 1990s [22], perhaps in part due to improvements in intensive care technol-
ogy, yet the prevalence of morbidity associated with infant HI remains undiminished [23, 24].
These sobering statistics should draw greater attention to the study of hypoxia in the develop-
ing brain, and the need for protective therapies to administer in these vulnerable infants.
2. The unique molecular landscape of the infant brain
Hypoxia exacts damage on the neonatal brain in a unique profile incomparable to the effect of
ischaemic stroke on the adult brain. The fundamental anatomy and chemistry of the immature
brain creates sites of increased sensitivity and resistance, many of which basic science is only
beginning to understand [16, 25]. This chapter will examine several key areas where the
physiology of the neonatal brain, and its susceptibility to hypoxic brain damage, requires
special consideration. The section will cover: the effect of structural immaturity on the devel-
opment of hypoxic ischaemic brain injury; alterations to the balance of cell death cascades; and
the surprising sex differences in severity of neonatal injury.
2.1. Hypoxia ischaemia and the structurally immature brain
The basic anatomy of the foetal brain is far from the oxygen-rich vasculated tissue familiar
from the adult brain, as summarised in Figure 1. Outlining the full range of age-dependent
processes is beyond the scope of this chapter, but one excellent review [25] expands substan-
tially on the information presented here.
The cerebral microvasculature is known to exhibit a significant risk of rupture, especially in
premature neonates [26, 27]. Fluctuations in cerebral blood flow have been correlated with
increased rates of intracerebral haemorrhage in infant patients [26, 28], an effect enhanced by
altered CO2 partial pressure in the blood [29] and haematocrit levels [30]. One influential
model [31] of the neonatal blood brain barrier (BBB) describes the cerebral vasculature as
undergoing a state of flux, remodelling vessels from basal-ganglia dense to a predominantly
cortex enriched state. This immature, incomplete vascular structure has not formed permanent
vessels by the time of birth. Research in animal models support this assessment, suggesting
that neonatal blood vessels are surrounded by fewer astrocyte end-feet [32], demonstrating
that the regulatory basement membrane which surrounds mature blood vessels is still forming
in the neonatal brain.
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The infant cerebrovasculature is often described as operating on a “pressure passive”
autoregulatory system [29]. Impaired vascular autoregulation has been reported as a risk factor
for poor clinical outcome in cases of perinatal and neonatal hypoxia ischaemia, or other infant
brain injuries [33, 34]. Low vascular tolerance of fluctuations in arterial CO2 partial pressure and
mean arterial blood pressure have been associated with severity of brain lesion in human
patients [35]. Nitric oxide synthetase (NOS) inhibitors were shown to be effective at increasing
tolerance of hypertension in neonatal pigs by increasing the upper cerebral blood flow limit for
vascular autoregulation [36], an effect not replicated in juvenile animals. Currently, the mecha-
nisms behind this “pressure passive “vascular regulation seen in the neonate remain unknown
[25], yet the success of NOS in preserving the cerebral vasculature of neonatal pigs suggests that
different molecules drive vascular autoregulation in the developing brain compared to the adult.
Another key differentiating factor between the adult and infant brain is the blood brain barrier.
The BBB is composed of capillary endothelial cells, astrocytes, pericytes, and the basement
membrane, forming a structure that regulates the transport of molecules between the blood
and the extracellular matrix of the brain. The accepted view in the literature for some time has
been that the immature BBB is less occlusive than that of the adult, enhancing brain damage
when the infant brain is subjected to hypoxia ischaemia [16, 25].
Some researchers have reported increased ‘leakage’ through the BBB in the immature brain. In
postnatal day 7 (P7) rat pups subjected to unilateral common carotid artery occlusion followed
by exposure to hypoxia, BBB permeability to immunoglobulin G (IgG) was increased compared
to P14 rats undergoing the same procedure [37]. When blood brain barrier transfer coefficient
was measured in perinatal and neonatal sheep, a greater vulnerability to hyperosmolarity was
Figure 1. Schematic summarising gross anatomical differences between the adult and neonatal human brain. Side profile
of whole neonatal (A) and adult (B) human brains. Sagittal cross-section of neonatal (C) and adult (D) human brains,
revealing structure visible by magnetic resonance imaging (MRI). Several key differences are highlighted between the
structure of the brain around birth and in the mature adult. BBB = blood brain barrier.
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detected compared to postnatal sheep [38]. Conversely, matrix metalloproteinase 9 (MMP9)
knock-out mice, which display reduced BBB permeability to IgG, were protected against neona-
tal HI, displaying reduced brain lesion size [39]. Pharmacophores which reduce BBB leakage are
also protective [40, 41].
However, assumptions concerning the vulnerability of the BBB are now coming under revision
[25]. Some experiments suggest that the increased BBB permeability in young rodents is a
secondary consequence of brain inflammation [42, 43], which suggests that reducing inflam-
mation in the hypoxic ischaemic brain may preserve BBB function. It is now known that tight
junctions, the molecular structures within the BBB responsible for its occlusive properties, are
present from the day embryonic blood vessels invade the foetal brain [16, 25, 44]. These foetal
BBB units have been demonstrated to possess occlusive properties, excluding water molecules
in the developing opossum brain [44, 45], and in piglets subjected to hypoxia ischaemia [46].
This brief overview highlights the importance of immature brain anatomy to the creating a
unique set of factors influencing the outcome of hypoxic ischaemic brain injury in the infant
brain. More basic research is needed to clarify the structure and functional capacities of the
cerebral microvasculature in the perinatal and neonatal brain. This information will be essen-
tial prior to development of future therapies for oral or intravenous administration.
2.2. Cell death in the neonatal brain: excitotoxicity, oxidative stress, and inflammation
There are several other areas of divergence between the infant and adult brain in addition to
vascular architecture. The immature brain also responds differently to major molecular cell
death pathways. Hypoxia ischaemia mediates brain damage through three overlapping molec-
ular cell death cascades: excitotoxicity, oxidative stress, and brain inflammation [16, 25],
summarised in Figure 2. The following section will outline the unique vulnerability of the
developing brain to each of these processes.
Excitotoxicity is a major cause of cell death in hypoxic ischaemic brain injury. During
excitotoxicity, over-activation of physiological glutamate neurotransmission leads to excessive
influx of positive ions through postsynaptic receptors, leading to cell death [16, 25, 47]. The
N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor stimulated during
excitotoxicity, is expressed at a substantially higher level in the developing brain compared to
the adult. In P6 rats, the NMDA receptor is expressed at 150–200% of adult levels [48]. The
combination of NMDA receptor subunits also differs in the perinatal period. The subunits
expressed in foetal rat favour prolonged calcium influx for a given excitation [49], increasing
the sensitivity of the immature brain to excitotoxicity. Intracerebral NMDA injection in rats
produces more extensive cell death in the neonate than in the adult [50]. Increased glutamate
concentrations have also been documented in the cerebrospinal fluid (CSF) of human infants
who have suffered severe HI injury [51].
Many factors contribute to the sensitivity of neurons to excitotoxic cell death, which is not
solely mediated by NMDA receptors. Much of this unique molecular landscape remains to be
understood. For example, it is known that neonatal brain is more prone to seizure activity than
the adult brain [52], with severe seizures potentially resulting in permanent brain damage by
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excitotoxic mechanisms. However, the mechanisms behind this sensitivity remain debated
[52, 53]. Perinatal exposure to hypoxia is known to elicit seizures in rodent models [54]. Yet it
is not clear if this is caused by the unique receptor complement of the developing brain,
transcriptional responses to hyperexcitability, long-term remodelling responses to inflamma-
tion, or the paradoxical excitatory activity of the neurotransmitter γ-amino butyric acid
(GABA) in the developing brain [53].
The oxidative stress molecular cell death cascade is integrally linked to that of excitotoxicity.
Oxidative stress is the term for high levels of free radical production generated during oxygen
metabolism under pathological conditions [55]. Hyperexcitability causes energy depletion,
mitochondrial dysfunction, and calcium ion accumulation in the cytoplasm, which in turn lead
to generation of free radicals, the damaging particles responsible for oxidative stress, which
then trigger increased excitotoxicity [16, 55]. Free radicals are atoms or molecules containing
an unpaired valence electron which makes these molecules highly chemically reactive and
capable of stripping electrons from other molecules in the brain, particularly in the mitochon-
dria [55].
In the adult brain, there exist several protective mechanisms which reduce the damage caused
by oxidative stress, such as stores of antioxidants and nucleic acid or protein repair enzymes,
which are not yet fully developed in the infant brain [56]. Expression of the enzyme nitric oxide
synthetase (NOS), which inhibits mitochondrial respiration and generates free radicals based
on NO, is up to 250% higher in the early postnatal rodent brain than in the adult [57]. Free
radical scavenging cascades, which render these highly reactive molecules harmless, are pre-
sent in the neonatal brain but less effective than in the adult brain [55, 58]. Immature oligoden-
drocytes were far less effective at degrading the free radical H2O2 in vitro, where scavenger
Figure 2. Schematic showing major molecular cascades contributing to the neuropathology of neonatal hypoxia ischae-
mia. (A) Schematic of an immature cortical neuron. (B) Sub-cellular molecular interactions in neonatal hypoxia ischaemia.
The inset corresponds to the area of the neurons in panel A outlined by the dotted line. Molecules involved in
excitotoxicity, oxidative stress, and inflammation closely interact. rER = rough endoplasmic reticulum, AIF = apoptosis-
inducing factors, free radicals in H2O2, O2
, NO, inflammatory molecules include interleukins (IL1β, IL6), tumour
necrosis factor alpha (TNFα), cytokines.
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enzyme catalase was expressed at constant levels throughout development, but glutathione
peroxidase was expressed at less than half of adult levels in oligodendrocytes from the neona-
tal brain [58]. There is also evidence that the scavenging cascades are less organised in the
developing brain, with some rodent studies documenting decreased expression of key
enzymes following exposure to hypoxia ischaemia [59].
In the first minutes after birth, the low oxygen environment of the foetus abruptly experiences
an increase in O2 partial pressure, which creates a pro-oxidant condition highly susceptible to
oxidative stress prior to the development of healthy protective mechanisms [60]. Another
potential reason for the vulnerability of the infant brain is the high polyunsaturated fat
content, particularly in the white matter, making this region vulnerable to lipid peroxidation
[61, 62]. Rodent studies have found that neonatal neurons may contain as little as a quarter of
the full complement of mitochondria expressed in adult cells, with those neonatal mitochon-
dria exhibiting altered calcium metabolism and internal matrix density as assessed by electron
microscopy [63]. The complex molecular response to free radical generation is still only begin-
ning to be understood in the infant brain.
The final factor known to contribute to neonatal hypoxic ischaemic brain injury is intracerebral
inflammation [16, 64]. In humans, intrauterine infection is strongly associated with preterm
birth and brain injury [64, 65]. In one long-term study, over 1000 premature infants diagnosed
with early- or late-onset sepsis at birth were assessed for neurodevelopmental outcome at the
age of five [66]. There was a strong correlation between sepsis at birth and diagnosis of cerebral
palsy at age five, however, there was no correlation between sepsis and milder cognitive
impairments. Although the infections were successfully treated in these patients, it is clear that
there are persistent effects of infection-induced inflammation.
Molecular biology experiments in animal models have directly linked brain inflammation to
neuronal cell death. Intracerebral inflammation triggered by injection of bacterial cell wall
component lipopolysaccharide (LPS) caused neurodegeneration in young mice via activation
of Toll-like receptor 4 [67]. One study investigating the effect of administering a single dose of
LPS prior to hypoxia ischaemia in neonatal rats found lesion size increased by more than 100%
compared to littermate animals that underwent hypoxia ischaemia alone [68]. This sensitivity
to hypoxia in the presence of brain inflammation has been termed the “double-hit hypothesis”
[69]. Interestingly, the injury-exacerbating effect of LPS on hypoxic ischaemic brain lesions may
be specific to the infant brain. In one investigation, low-dose pre-treatment with intrauterine
LPS increased injury severity in neonatal hypoxic ischaemic mouse, whereas the same pre-
treatment was protective in adult animals [70, 71].
Despite the potential for inflammation to cause injury in animal models of infant hypoxia
ischaemia, not all elements of the brain’s inflammatory response are necessarily detrimental.
The resident macrophages of the central nervous system, known as microglia, are activated
within hours of the hypoxic ischaemic insult [72]. Microglia are known to produce a range of
cytokines, excitotoxic neurotransmitter glutamate, and molecules known to induce oxidative
stress such as nitric oxide and free radicals [16]. Additionally, chloroquine and minocycline,
drugs which inhibit microglia and monocytes, decreased lesion size in a mouse model of
neonatal hypoxia ischaemia [73]. However, microglia are complex secretory powerhouses with
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multiple active states, and there is growing support for a balanced understanding of these
neuronal support cells as capable of causing both damaging and beneficial effects in neonatal
hypoxia ischaemia [74, 75]. For example, when microglia were depleted in the brains of
neonatal mice, lesion volume increased, along with the concentration of various cytokines
and reactive oxygen species in the neonatal brain [76]. This suggests a neuroprotective func-
tion for microglia, at least under specific conditions.
2.3. Sexual dimorphism in the response to neonatal hypoxia ischaemia
One finding clearly illustrates how much remains to be understood about the neuropathology
of neonatal hypoxia ischaemia. This is the recent discovery of sexual dimorphism in the
developmental outcome of HI in human patients [77, 78]. Male babies are at higher risk of
cerebral palsy than females [79]. Not only are motor deficits significantly more severe in male
infants [77], but structural magnetic resonance imaging (MRI) has demonstrated a qualita-
tively different pattern of injury in males and females. One study reported that white-matter
injury patterns predominated in male babies, whereas females were more likely to demon-
strate a grey-matter injury pattern [80]. These relatively recent discoveries led to reanalysis of a
clinical trial of prostaglandin inhibitor indomethacin as a preventative treatment in infants at
high-risk of intraventricular haemorrhage [77, 81]. When cognitive and motor development
were assessed in a mixed-sex group at age 3, there was no difference between treated and
untreated groups. However, when boys and girls were analysed separately, the anti-
inflammatory drug improved functionality in boys given indomethacin compared to boy
who did not receive treatment. New contributing factors for hypoxic ischaemia injury continue
to be uncovered, and this surprising revelation reinforces the argument that our current
models should remain under revision.
The physiological basis of this sexual dimorphism remains poorly understood [16, 77, 78].
Neuronal culture models have identified sex-specific differences in cell death cascades induced
by hypoxia in vitro. One of the first studies to suggest a molecular basis for this sexual dimor-
phism cultured XX (female) and XY (male) neurons separately and triggered neuronal cell death
by administering nitric oxide (NO) and glutamate [82]. The mitochondria of male and female
neurons released different molecules, and the male neurons were less able to maintain antioxi-
dant expression. This finding has been expanded upon considerably since. The putative treat-
ment 2-iminobiotin appears to have different effects on neurons from male and female rats [83].
In males, there was no significant effect, whereas female rats showed decreased activation of the
cytochrome C cascpase-3 pathway, and its downstream cell death markers. Another investiga-
tion found that female neonatal rats expressed greater levels of cleaved caspase-3, the activated
form of an important cell death promoting molecule, than male brains, although there was no
difference between the sexes in nitrotyrosine or autophagy [84].
Sexual dimorphism in neonatal hypoxia ischaemia is receiving increasing attention. This is an
expanding area of research, with recent in vivo studies uncovering unexpected results. There is
now robust evidence that the increased vulnerability seen in male human patients extends
to rodents [77, 84]. When equivalent procedures were used to generate hypoxia ischaemia in
rats over a range of developmental stages, the only significant difference in lesion outcome
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between the sexes was detected at a perinatal age, with no difference in older rat pups or fully-
developed adults [84]. Animal models of neonatal HI support a fundamental difference in
mitochondrial respiratory function in the developing male and female brain [85, 86], with female
mitochondria posited as more resilient. Mitochondrial function may not fully explain the differ-
ence between the sexes, as evidence is now emerging that drugs targeting neurotransmitter
receptors may only be effective in one sex, males [87]. Sex hormone therapy, such as progesterone
treatment, is protective against HI injury inmale rats but had no effect in females [78, 88]. Despite
suggestions that the adult brain’s response to ischaemic stroke may also be sex-dependent [77],
the evidence currently suggests that this difference is largely a neonatal phenomenon.
3. Treatments of neonatal hypoxia ischaemia
Despite the high rates of disability in human survivors of neonatal hypoxia ischaemia [4, 16],
only one treatment is currently licenced in the UK: hypothermia. This therapy reduces the
infant’s body or head to approximately 33C [16, 89]. Hypothermia was first demonstrated to
improve survival in cases of cardiac arrest [90], and has since been applied as a neuropro-
tective treatment in acute neonatal hypoxia ischaemia patients [89, 91]. One meta-analysis of
over 1200 infants found that hypothermia reduced death and neurological handicaps at
18 months follow-up across all severities of neonatal hypoxia ischaemia [89].
However, hypothermia alone is not sufficient to prevent all brain injury or neurological symp-
toms [4, 16, 89]. Since the discovery of the neuroprotective effect of hypothermia, little progress
has been made towards additive therapies. Few potential treatments have reached clinical
trials. The development of novel treatments to supplement hypothermia is imperative. In this
section, current research into novel treatments for neonatal hypoxia ischaemia will be
reviewed and approaches for therapy development will be evaluated.
3.1. Review of therapies under development for infant hypoxia ischaemia
Two additional interventions have been deemed safe to trial in neonates. Resuscitation at room
temperature [92] and xenon gas administration [93] have been investigated in a clinical envi-
ronment alongside hypothermia. The limited success reported in these studies is now under
speculation. Recent randomised clinical trials have demonstrated that although xenon gas is a
safe treatment, there is little or no therapeutic effect of combined hypothermia and xenon gas
in moderate and severe cases of neonatal HI at 18 months follow-up [94]. A parallel experi-
ment in rats found that xenon made no difference to lesion size or neuronal cell numbers in
cases of severe hypoxia ischaemia [95].
Pharmacological agents have also been investigated in human neonatal patients, resulting in
limited success. Barbiturate anticonvulsants had no effect on long-term neurological develop-
ment when given to hypoxic ischaemic neonates [96]. A more promising result from recent
clinical studies suggests that high-dose erythropoietin (EPo) treatment in term neonates
reduces disability [97]. However, even proponents of this potential treatment advise caution
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in interpreting early results. The therapy does not completely prevent neurological symptoms.
There is hope for erythropoietin as a future additive treatment, yet the field should be
concerned that this is currently the only pharmacological molecule being pursued in clinical
trials for neonatal hypoxia ischaemia.
Many more small molecules are being investigated in animal models of neonatal hypoxia
ischaemia, where the translational value of the research, and the safety of the treatment in
vulnerable newborns, remain uncertain. For example, free radical scavenger N-acetylcysteine
and systemic hypothermia reduced infarct volume after focal hypoxic ischaemic injury in rats
[98, 99]. Another free radical scavenger, allopurinol, reduced cerebral oedema and neuropath-
ological damage [99, 100].
One example of the difficulty involved in selecting targets for new therapies is the lack of
clinical translation of the extensive work on NMDA receptor-mediated excitotoxicity in the
neonatal hypoxic ischaemic brain. Drugs that block NMDA receptors are protective against HI
injury in neonatal rodent models [101]. Despite the efficacy of NMDA receptor antagonists in
reducing infarct volumes in rats, this work has not been pursued in humans as intact NMDA-
mediated classical neuronal plasticity is essential for normal brain development [16, 102, 103].
Effective NMDA antagonists could cause more damage to the circuitry of the neonatal brain
than is justified by their anti-excitotoxicity function, undermining the medical philosophy
enshrined in the Hippocratic oath: to do no harm.
There are several novel treatments being developed by dedicated scientists, although it is
extremely difficult to predict which of these will be deemed safe enough to allow clinical trials
in the developing brain. Perhaps the translation from bench to bedside for putative treatments
could be improved through a different approach to treatment selection and funding. Some
essential factors demanding consideration at the earliest point in treatment development are
outlined below.
3.2. Proposed approaches to therapy development for infant hypoxia ischaemia
New approaches are required to identify potential treatments for neonatal hypoxia ischaemia
which will be better suited to advance into clinical trials. Three essential properties must be
satisfied in a new therapy. These have been suggested in a previous publication I authored
[16], and are summarised in Figure 3. First, all potential treatments should be safe for vulner-
able neonates and not interfere with essential developmental milestones. Second, treatments
should be specific, to avoid extreme adverse effects in vulnerable infants. And third, an ideal
treatment would target molecules common to the excitotoxicity, oxidative stress, and inflam-
mation pathways. Targeting common mediators would allow a single therapy to be efficacious
against multiple mechanisms of brain damage, instead of merely eliciting a reshuffle to favour
a different method of cell death [62, 102]. These three qualities can be summarised as safety,
specificity, and breadth.
The suitability of any future small molecules for use in human neonates will depend greatly on
the severity of any adverse effects on brain development. A wide range of molecules contribute
to healthy brain development in the neonatal period [16, 103, 104], a time of widespread
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remodelling and plasticity within the brain. Selecting molecular targets known to be expressed
in the neonatal brain could reduce the chances of general toxicity, but does not preclude the
possibility that endogenous proteins may have a narrow therapeutic range, with slight
increases or decreases interfering with development. Future studies of potential treatments
should examine developmental plasticity processes, to ensure safety in the neonatal brain.
Specificity is also a desired characteristic of any potential pharmacological therapy for neo-
nates, as faithfulness of a single molecular target minimises the likelihood of off-target side-
effects. The cardiovascular and respiratory systems of neonates are vulnerable in premature
birth and following hypoxic ischaemia injury [5, 8], so brain-specific neuroprotective treat-
ments are desirable. Molecular specificity is essential in addition to organ specificity. Extensive
characterisation of the binding partners of not only the pharmacological molecule, but also its
biological molecular target, is time-consuming but essential work if a therapy is to be esti-
mated as safe enough for trial in human neonates. As high-throughput screening methods are
increasingly refined for use throughout the pharmaceutical industry [105, 107], capturing
specificity is becoming a realistic research goal.
Breadth of action is essential for the efficacy of a therapy designed for neonatal hypoxia
ischaemia, in which a wide range of neuronal death pathways are active simultaneously in
Figure 3. Schematic depiction of proposed filters for putative therapies for infant hypoxia ischaemia. All putative
treatments should satisfy safety prior to investigation in human infants. Specificity may also decrease off-target effects,
and breadth may increase treatment efficacy. Several current treatments are listed by which criteria these satisfy.
HIF1 = hypoxia inducible factor 1, tPA = tissue plasminogen activator, NMDA-R = N-methyl-D-aspartate receptor, EPo =
erythropoietin.
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the injured brain. These cascades, which include excitotoxicity, oxidative stress, and inflamma-
tion, are not entirely independent of one another. It may be possible to identify a “master
regulator”. This hypothetical single molecule would dampen multiple brain damage path-
ways, inhibiting a key activator (or activators) of each respective process, and perhaps trigger
other neuroprotective cascades. But how probable is it that a “master regulator” will be
discovered? Is it possible that one has already been documented and simply remains to be
exploited?
The concept of a “master regulator” for any complex disease appears enticing, but is its
promise only linguistic trickery? Identification of candidate proteins will not be a simple
process, likely requiring many experiments spanning multiple methods. One possible starting
point is microarray data collected following neonatal hypoxia ischaemia in rodents [106, 107].
Microarrays are highly sensitive to the time of tissue collection post-injury, and do not detect
changes in functional protein content mediated by translational modification or secretion. For
example, no published microarrays detected changes in tissue plasminogen activator (tPA) or
hypoxia inducible factor 1 (HIF1) transcription, although these proteins play a substantial role
in injury pathogenesis [108, 109]. Generating a neonatal hypoxia ischaemia ‘secretome’ [110]
could help identify the earliest changes in protein activity directly following neonatal brain
injury.
Some proteins are already known to span multiple cell death cascades [16, 62, 102]. These are
clearly the most accessible candidates for “master regulator” properties. NMDA receptors,
major mediators of neuronal death by excitotoxicity, can be directly or indirectly activated by
free radicals, combining two lethal molecular cascades often treated as separate in the litera-
ture [16, 25, 47]. Inflammatory pathways also mediate excitotoxicity and oxidative stress. In
rodents, pre-treatment with IL-1ß, IL-6, IL-9, or TNF-α enhances brain damage caused by
NMDA agonists [16, 64, 73]. It is these overlaps between cascades at which a “master regula-
tor” could act. One candidate is HIF1 [109]. This transcription factor is known to regulate a
minimum of 60 genes, including the putative therapeutic molecule erythropoietin, several
growth factors, and mitochondrial proteins. Another possible “master regulator”, tissue plas-
minogen activator, is currently one of the best-documented possibilities [16, 108]. tPA has
established roles crossing boundaries between excitotoxicity, oxidative stress, and brain
inflammation. The relative dearth of candidates proposed here perhaps reflects our incomplete
knowledge of the molecular mechanisms underpinning neonatal hypoxic ischaemic brain
damage. There is no clear single “master regulator” protein documented in the literature of
this complex neurodevelopmental disorder. However, this does not restrain future experi-
menters from seizing on those few currently supported candidates for further development.
4. Conclusions
As the most common single cause of infant mortality and morbidity globally, neonatal and
perinatal hypoxia ischaemia deserve wide recognition and funding within the research com-
munity. These conditions require careful examination in animal models closely matched to the
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level of brain development at birth in humans, as there is a plethora of differences between the
adult and infant brain which create infant-specific challenges for understanding neuropathol-
ogy and developing new therapies. Infant-specific obstacles also exist, as any treatment should
not interfere with normal brain development, or the vulnerable infant cardiovascular system.
Despite these constraints, it should be possible to develop novel therapeutics closely guided by
the criteria of safety, specificity, and breadth. Current research has suggested some promising
candidate neuroprotective treatments, such as erythropoietin and tissue plasminogen activa-
tor, and these could yet inform future approaches to therapeutic development.
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